IGF-I R/IGF1R Antibody (33255) [Unconjugated]

Western blot shows lysates of NTera‑2 human testicular embryonic carcinoma cell line, SK‑Mel‑28 human malignant melanoma cell line, and G361 human melanoma cell line. PVDF membrane was probed with 1 µg/mL of Mouse Anti-Human/Mouse IGF-I R/IGF1R Monoclonal Antibody (Catalog # MAB391) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for IGF-I R/IGF1R at approximately 275 kDa (as indicated). This experiment was conducted under non-reducing conditions and using Immunoblot Buffer Group 2.

MCF‑7 human breast cancer cell line was stained with Mouse Anti-Human IGF‑I R/IGF1R Monoclonal Antibody (Catalog # MAB391, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram) followed by anti-mouse IgG PE-conjugated secondary antibody (Catalog # F0102B). View our protocol for Staining Membrane-associated Proteins.

IGF-I R/IGF1R was detected in immersion fixed MCF‑7 human breast cancer cell line (positive staining; left panel) and HDLM human Hodgkin's lymphoma cell line (negative staining; right panel) using Mouse Anti-Human/Mouse IGF-I R/IGF1R Monoclonal Antibody (Catalog # MAB391) at 3 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to cell membrane in MCF-7 cell line. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

IGF-I R/IGF1R was detected in perfusion fixed paraffin-embedded sections of mouse heart using Mouse Anti-Human/Mouse IGF-I R/IGF1R Monoclonal Antibody (Catalog # MAB391) at 15 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to plasma membrane and cytoplasm. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Recombinant Human (rh) IGF‑I/IGF-1 (Catalog # 291-G1) stimulates proliferation in the MCF‑7 human breast cancer cell line in a dose-dependent manner (orange line). Proliferation elicited by rhIGF‑I/IGF-1 (6 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human/Mouse IGF-I R/IGF1R Monoclonal Antibody (Catalog # MAB391). At 11 µg/mL, this antibody will neutralize 50-75% rhIGF-1 induced activity.

• Reactivity: Hu, Mu
• Applications: WB, Flow, IHC, B/N, ELISA(Cap), ICC/IF
• Clone: 33255
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

IGF-I R/IGF1R Antibody (33255) [Unconjugated] Summary

• Immunogen: S. frugiperda insect ovarian cell line Sf 21-derived recombinant human IGF-I R/IGF1R
  Glu31-Asn932
  Accession # P08069
• Specificity: Detects human IGF-I R/IGF1R in sandwich ELISAs and Western blots. Detects mouse IGF-I R/IGF1R in Immunohistochemistry. In sandwich immunoassays, less than 0.15% cross-reactivity or interference was observed with recombinant human (rh) IGF-I, rhIGF‑II, rhIL‑3 R alpha , rhIL‑9 R, and rhTGF‑ beta RII.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: IGF1R
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Flow Cytometry 0.25 ug/10^6 cells
  • Immunocytochemistry 3-25 ug/mL
  • Immunohistochemistry 5-25 ug/mL
  • Neutralization
  • Western Blot 1 ug/mL
• Application Notes: ELISA Detection: Human IGF-I R Biotinylated Antibody (Catalog number BAF391)
  Standard: Recombinant Human IGF-I R (Catalog number 391-GR)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IGF-I R/IGF1R Antibody (33255) [Unconjugated]

• CD221 antigen
• CD221
• EC 2.7.10
• EC 2.7.10.1
• IGF1R
• IGF-1R
• IGF-I R
• IGF-I receptor
• IGFIR
• IGF-IR
• IGFR
• insulin-like growth factor 1 receptor
• Insulin-like growth factor I receptor
• JTK13
• MGC142170
• MGC142172
• MGC18216
• soluble IGF1R variant 1
• soluble IGF1R variant 2

Background

Insulin-like growth factor I receptor (IGF-I R) is a disulfide-linked heterotetrameric transmembrane protein consisting of two alpha and two beta subunits. Both the alpha and beta subunits are encoded within a single receptor precursor cDNA. The proreceptor polypeptide is proteolytically cleaved and disulfide-linked to yield the mature heterotetrameric receptor. The alpha subunit of IGF-I R is extracellular while the beta subunit has an extracellular domain, a transmembrane domain and a cytoplasmic tyrosine kinase domain. IGF-I R is highly expressed in all cell types and tissues. Essentially all of the biological activities of IGF-I and -II have been shown to be mediated via IGF-I R.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IGF-I R/IGF1R Antibody (MAB391)(18)

Publications using MAB391

• Miyagawa, K;Tenshin, H;Mulcrone, PL;Delgado-Calle, J;Subler, MA;Windle, JJ;Chirgwin, JM;Roodman, GD;Kurihara, N; Osteoclast-derived IGF1 induces RANKL production in osteocytes and contributes to Pagetic lesion formation JCI insight 2023-06-20 [PMID: 37338990] (Neutralization, Mouse)
• T Khan, AM Seddon, AG Dalgleish, S Khelwatty, N Ioannou, S Mudan, H Modjtahedi Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer Oncol Rep, 2020-10-22;0(0):. 2020-10-22 [PMID: 33125153] (Flow Cytometry, Human)
• J Li, E Weber, S Guth-Gunde, M Schuleit, A Kuttler, C Halleux, N Accart, A Doelemeyer, A Basler, B Tigani, K Wuersch, M Fornaro, M Kneissel, A Stafford, BR Freedman, DJ Mooney Tough Composite Hydrogels with High Loading and Local Release of Biological Drugs Adv Healthc Mater, 2018-02-14;0(0):. 2018-02-14 [PMID: 29441702] (ELISA Capture, Mouse)
• Y Neuzillet, E Chapeaubla, C Krucker, L De Koning, T Lebret, F Radvanyi, I Bernard-Pi IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer BMC Cancer, 2017-09-07;17(1):636. 2017-09-07 [PMID: 28882129] (Neutralization, Human)
• Helmout Modjtahedi Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs Int. J. Oncol., 2016-09-05;49(5):1825-1838. 2016-09-05 [PMID: 27599579] (Flow Cytometry, Western Blot, Human)
• M Gschweitl, A Ulbricht, CA Barnes, RI Enchev, I Stoffel-St, N Meyer-Scha, J Huotari, Y Yamauchi, UF Greber, A Helenius, M Peter A SPOPL/Cullin-3 ubiquitin ligase complex regulates endocytic trafficking by targeting EPS15 at endosomes Elife, 2016-03-23;5(0):. 2016-03-23 [PMID: 27008177] (Western Blot, Human)
• Garwood C, Ratcliffe L, Morgan S, Simpson J, Owens H, Vazquez-Villasenor I, Heath P, Romero I, Ince P, Wharton S Insulin and IGF1 signalling pathways in human astrocytes in vitro and in vivo; characterisation, subcellular localisation and modulation of the receptors. Mol Brain, 2015-08-22;8(0):51. 2015-08-22 [PMID: 26297026] (Neutralization, Human)
• Cardillo T, Trisal P, Arrojo R, Goldenberg D, Chang C Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. BMC Cancer, 2013-04-01;13(0):170. 2013-04-01 [PMID: 23548153] (Flow Cytometry, Human)
• Suh H, Zhao M, Derico L, Choi N, Lee S Insulin-like growth factor 1 and 2 (IGF1, IGF2) expression in human microglia: differential regulation by inflammatory mediators. J Neuroinflammation, 2013-03-12;10(0):37. 2013-03-12 [PMID: 23497056] (ICC, Human)
• Jacques C, Holzenberger M, Mladenovic Z Proinflammatory actions of visfatin/nicotinamide phosphoribosyltransferase (Nampt) involve regulation of insulin signaling pathway and Nampt enzymatic activity. J. Biol. Chem., 2012-03-07;287(18):15100-8. 2012-03-07 [PMID: 22399297] (Neutralization, Human)
• Massoner P, Ladurner Rennau M, Heidegger I, Kloss-Brandstatter A, Summerer M, Reichhart E, Schafer G, Klocker H Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-beta treatment. Am. J. Pathol., 2011-10-06;179(6):2905-19. 2011-10-06 [PMID: 21983635] (IHC-P, Human)
• Wang N, Fallavollita L, Nguyen L, Burnier J, Rafei M, Galipeau J, Yakar S, Brodt P Autologous bone marrow stromal cells genetically engineered to secrete an igf-I receptor decoy prevent the growth of liver metastases. Mol. Ther., 2009-04-14;17(7):1241-9. 2009-04-14 [PMID: 19367255] (ELISA Development, Human)
• Back K, Arnqvist HJ Changes in insulin and IGF-I receptor expression during differentiation of human preadipocytes. Growth Horm. IGF Res., 2008-08-09;19(2):101-11. 2008-08-09 [PMID: 18693051] (ELISA Development, Human)
• Riccioni R, Senese M, Diverio D, Riti V, Mariani G, Boe A, LoCoco F, Foa R, Peschle C, Sporn M, Testa U Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels. Leuk. Res., 2008-03-04;32(8):1244-58. 2008-03-04 [PMID: 18304628] (Flow Cytometry, Human)
• Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, Holy X, Gorin NC, Lopez M, Doucet C, Lataillade JJ Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk. Lymphoma, 2007-10-01;48(10):2032-41. 2007-10-01 [PMID: 17917971] (Flow Cytometry, Human)
• Riccioni R, Diverio D, Mariani G, Buffolino S, Riti V, Saulle E, Petrucci E, Cedrone M, Lo-Coco F, Foa R, Peschle C, Testa U Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with monocytic features of leukemic blasts. Stem Cells, 2007-04-19;25(8):1862-71. 2007-04-19 [PMID: 17446561] (Flow Cytometry, Human)
• Spicer LJ, Aad PY Insulin-like growth factor (IGF) 2 stimulates steroidogenesis and mitosis of bovine granulosa cells through the IGF1 receptor: role of follicle-stimulating hormone and IGF2 receptor. Biol. Reprod., 2007-03-14;77(1):18-27. 2007-03-14 [PMID: 17360960] (Western Blot, Bovine)
• Quirk SM, Cowan RG, Harman RM The susceptibility of granulosa cells to apoptosis is influenced by oestradiol and the cell cycle. J. Endocrinol., 2006-06-01;189(3):441-53. 2006-06-01 [PMID: 16731776] (Neutralization, Bovine)

Bioinformatics

• Gene Symbol: IGF1R
• Uniprot:
  • P08069()